CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech and its use in the manufacture and sale of Comirnaty®, BioNTech and Pfizer's mRNA COVID-19 vaccine.
In a press release dated July 5, 2022, CureVac announces they have filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights, utilized in the manufacture and sale of Comirnaty®, BioNTech and Pfizer's mRNA COVID-19 vaccine.
"The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTech's SARS CoV-2 mRNA vaccine, among others. These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression, as well as mRNA vaccine formulations specific to SARS CoV-2 vaccines", the press release states.
The press release does not mention how much they seek to be financially compensated. However, this may be a substantial amount considering the large distribution of the Covid-19 vaccine though out the world.
CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty® by BioNTech and its partner Pfizer.
The BioNTech's stock price has fallen dramatically since it reached its top at approximately $389, in August 2021.
Read the Full Press release